Startups
Die Kurzprofile der Startups finden Sie hier:
Kurzprofile
-
Medical field: ICU; Primary care; palliative care
Product type: AI-enabled bed-exit prevention solution
Growth stage: Commercially ready
Team: 19 employeesDescription of product:
PreSAGE – an AI-enabled patient-monitoring solution. The solution is based on three key design principles – non-contact, non-intrusive and continuous monitoring, where high fall-risk patients are kept safe in the ward environment. When a bed-exit is picked-up by the AI, an external alarm notification is triggered that leads to timely staff intervention and therefore preventing any potential falls.Desired project goal:
Deploy PreSAGE devices in ICU environment, particularly for bed-exit monitoring in this specialized environment. CoNEX will provide PreSAGE devices and accessories for approximately 4 rooms, for a proposed period of 3 months. CoNEX will facilitate the set-up, configuration, onboarding onto network infrastructure, training and study operationalization at Charite in consultation with stakeholders. As a digital solution, CoNEX can support the solution via remote access, and hold regular meeting sessions with Charite team on the system performance typically on a monthly basis. The study can
include comparisons in care protocols with the assistance of PreSAGE solution for fall risk management. Additionally, PreSAGE can be extended to study patient condition monitoring based on activity intensity analytics, with the potential to explore predicting patient condition in the future. -
Medical field: ICU; Paliative medicine; Primary care; Prevention; Gastroenterology
Product type: Medical Device, Diagnostics, and Therapeutics; Care Settings and Processes
Growth stage: Pre-Lounch
Team: 5 employeesDescription of product:
Puffinder is a Nasogastric Tube Tip Locator (NTL) that confirms a nasogastric (NG) tube is in a patient's stomach when the length of the inserted tube reaches the pre-estimated length that should reach the stomach. This product is designed for adult patients and is to be used in a clinical and clean home environment.Desired project goal:
We want to test-bed and validate Puffinder with Charité. The study aims to provide clinical evidence that Puffinder’s efficacy and safety are clinically acceptable in Germany and the rest of Europe. -
Medical field: all
Product type: Generative AI, advanced technologies
Growth stage: Launched in May 2025
Team: 7 Employees by Jan 2026Description of product: E nigma Health is an AI healthcare workflow company dedicated to transforming operations through sovereign AI workflow agents. These agents are designed to automate complex, document-centric processes across healthcare systems—while maintaining the highest standards of compliance, data privacy, and clinical integrity. At the heart of Enigma Health’s innovation is its expertise in orchestrating fine-tuned, purpose-built language models. Specifically optimized for labor-intensive healthcare workflows, these models deliver higher accuracy and faster processing speeds with significantly lower computational demands. Unlike cloud-based solutions, Enigma’s proprietary orchestration runs entirely onpremises, providing unmatched security and safeguarding sensitive health data. The company’s flagship product, the Enigma AI Platform, integrates seamlessly with existing healthcare infrastructure. Featuring an intuitive ambient search interface, it empowers users to complete workflows with exceptional speed, efficiency, and ease—enabling healthcare organizations to focus more on patient care and less on administrative burden.
Desired project goal: We would like to validate these modules with Charite. The (ii) clinical audit and (iii) clinical financial module are AI -powered solutions aligned with Charite’s interest for AI-Powered Trial Co-Pilots (LLM/NLP). For Enigma Health, this would also validate the solutions’ ability to adapt to different healthcare operational workflows and data dictionaries.
-
Medical field: Gastroenterology; Hepatology; Endocrinology; Digital Pathology services
Product type: Medical device; AI-analysis, diagnostics, advanced technologies
Growth stage: expanding
Team: 25Description of product:
MASH RPI is a risk stratification tool designed to assess the likelihood of hepatic decompensation in patients with metabolic dysfunctionassociated steatohepatitis (MASH). Using a baseline liver biopsy image generated through second harmonic generation (SHG) imaging, the tool automatically extracts and quantifies multiple collagen parameters, which are then integrated into a single predictive index. MASH RPI has demonstrated superior predictive accuracy for longterm clinical outcomes, compared to traditional NASH-CRN fibrosis staging (Kendall et. al, 2005). This can enable clinicians to more
effectively manage MASH patients based on individual risk profiles.Desired project goal:
The company would like to conduct an extensive on-site validation of MASH RPI using retrospective patient cohorts from the European population. The objective is to generate region-specific clinical evidence to demonstrate the tool’s applicability and clinical utility in the EU, supporting its eventual deployment as a clinical diagnostic test. This collaboration will also contribute to global clinical evidence generation to enable broader market access and support reimbursement by aligning with international payer expectations. -
Medical field: Cancer Diagnostics – Therapy selection
Product type: Ex-vivo drug response + Small Data AI
Growth stage: Commercial ready
Team: 16Description of product:
Optim.AI™ combines small data AI and biological experiments to identify the optimal outcome to thousands of possible drug-dose combinations. The Optim.AI™ platform, developed by KYAN Technologies, combines small-data artificial intelligence to evaluate the drug response/resistance profile of tumor samples against a panel of clinically relevant agents and their combinations. This process generates ranked treatment options based on normalized cell viability (NCV) values, with lower values indicating greater drug effect. Optim.AI™ has demonstrated clinical accuracy exceeding 80% across more than 20 cancer indications, supporting treatment decisions in both hematologic malignancies and solid tumors. The platform is operated in KYAN’s central laboratory in Singapore, which is approved by the Singapore Ministry of Health (MOH) as a clinical laboratory and accredited by the College of American Pathologists (CAP) and ISO 13485. Optim.AI™ enables clinicians to prioritize therapies, reduce ineffective treatments, and align care strategies with each patient’s unique tumor biology. Optim.AI™ is being commercialized in Singapore, Malaysia, Thailand, Indonesia, and Philippines. In 2026, Optim.AI™ will be launched in the United States through a strategic collaboration with Mayo Clinic.Desired project goal:
Sample Viability Assessment for International Shipment from Europe to Singapore; Observational Studies-Patients receive a complete report on the efficacy of eight to 12 drugs commonly used in the respective indication and their combinations. This study aims to assess the feasibility of Optim.AI™ in Germany and the clinical relevance of the test results.